Pediatric summit explores growing issue of risk vs. benefits of rare disease drugs

An official from the National Institutes for Health told a crowd on Thursday that the medical community needs to take more risks when treating rare, deadly diseases in children — a viewpoint that could just as easily be applied to the drug approval process...